Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal SCRIPTA SCORE Scientific Medical Journal Jurnal Hukum dan Etika Kesehatan (JHEK)
Syafira, Fara
Unknown Affiliation
Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : SCRIPTA SCORE Scientific Medical Journal

 1 
The Potential Of Antisense Oligonucleotides (ASO) Through Inhalation Based On Gold Nanoparticle (AuNP) Delivery System In Inhibiting SARS-CoV-2 Replication And Transcription Deanasa, Raehan Satya; Afladhanti, Putri Mahirah; Syafira, Fara
SCRIPTA SCORE Scientific Medical Journal Vol. 4 No. 1 (2022): SCRIPTA SCORE Scientific Medical Journal
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/scripta.v4i1.8384

Abstract

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This virus infects the respiratory, digestive, and nervous systems with a rapid transmission and a fairly high mortality rate. However, there has been no specific therapy to treat COVID-19. Previous studies have shown that antisense oligonucleotide (ASO) has good efficacy in DNA and RNA viral infections. This literature review aims to investigate the potential of inhaled ASO based on gold nanoparticles (AuNp) delivery system in inhibiting the replication and transcription of SARS-CoV-2. Literature searching using several databases, such as Google Scholar, Science Direct, ResearchGate, and NCBI. Inclusion and exclusion criteria are used to eliminate the journals that does not match the criteria, thus 28 journals are obtained. The results show that ASO has the potential to inhibit the replication and transcription of the SARS-CoV-2 virus through different mechanisms by binding to the target RNA and modulating the viral protein synthesis. One form of ASO modification that is often used is LNA GapmeR. LNA GapmeR stimulates viral RNA cleavage and can be administered by inhalation with nebulized ASO solution. AuNP as an ASO delivery system through inhalation can reduce toxicity and increase ASO concentrations in reaching target cells. Therefore, ASO therapy with AuNP through inhalation needs to be considered for COVID-19 treatment. Further clinical study about the ideal delivery system and optimal dosage of ASO based AuNP via inhalation for COVID-19 are needed to investigate soon.
The Potency of Oral L-Arginine Suplementation Based on Chitosan-Coated Gold Nanoparticles (c-AuNPs) as Preeclampsia Prevention in Pregnant Women Syafira, Fara; Deanasa, Raehan Satya Deanasa; Afladhanti, Putri Mahirah Afladhanti
SCRIPTA SCORE Scientific Medical Journal Vol. 4 No. 1 (2022): SCRIPTA SCORE Scientific Medical Journal
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/scripta.v4i1.8392

Abstract

Preeclampsia is a multi-systemic hypertensive disorder in pregnant women after two weeks of gestation and can cause complications in about 6-10% of all pregnancies. The incidence of preeclampsia in Indonesia is 128,273/year or about 5.3%. However, the handling of preeclampsia in Indonesia is still not optimal. This disease is difficult to detect and often appears suddenly, so prevention efforts need to be taken as an essential step in reducing morbidity and mortality due to this disease. Previous studies have shown that L-Arginine exhibits potential properties in preventing preeclampsia. This literature review aims to determine the potential for oral L-Arginine supplementation to prevent preeclampsia in pregnant women. Search for literature using search engines such as Google Scholar, Science Direct, ResearchGate, and NCBI. Inclusion and exclusion criteria are used to eliminate unrelated journals so 38 journals are obtained. L-Arginine has great potential as a preventive supplementation of preeclampsia by increasing the vascular NO synthesis where NO deficiency in pregnant women can induce changes in the uteroplacental structure. Supplementation of the dietary L-Arginine at a low dose of 3 g/day for three to four weeks is required in early pregnancy. The use of chitosan-coated gold nanoparticles (c-AuNPs) as encapsulation on a protein increases the bioavailability of oral supplementation and improves the patient's clinical state. Further research regarding the effectiveness of L-Arginine supplementation orally with c-AuNPs and the optimal dosage as a preeclampsia preventive supplement is needed.
Co-Authors Afladhanti, Putri Mahirah Afladhanti, Putri Mahirah Afladhanti Baharul Iman, Muhammad Deanasa, Raehan Satya Deanasa, Raehan Satya Deanasa